Dose equivalency and efficacy of biosimilar erythropoietin stimulating agents: Data from real clinical practice

Recently, biosimilar erythropoietin stimulating agents become available in Kazakhstan. Important properties of the biosimilar such as dose equivalency to the original medicine (originator) and the ability to maintain hemoglobin target levels remain insufficiently described in many clinical settings....

Descripción completa

Detalles Bibliográficos
Autores principales: Gaipov, Abduzhappar, Issanov, Alpamys, Mursalova, Zhanar, Tulegenova, Nazia, Kakim, Zoya, Baizakov, Mukhit, Tuganbekova, Saltanat, Aljofan, Mohamad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287030/
https://www.ncbi.nlm.nih.gov/pubmed/32524766
http://dx.doi.org/10.1002/prp2.594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287030/
https://www.ncbi.nlm.nih.gov/pubmed/32524766
http://dx.doi.org/10.1002/prp2.594

Ejemplares similares